Abstract

Autosomal recessive juvenile Parkinsonism (ARJP) is an inherited neurodegenerative disease in which 50% of affected individuals harbor mutations in the gene encoding the E3 ligase parkin. Parkin regulates the mitochondrial recycling pathway, which is induced by oxidative stress. In its native state, parkin is auto-inhibited by its N-terminal ubiquitin-like (Ubl) domain, which blocks the binding site for an incoming E2∼ubiquitin conjugate, needed for parkin's ubiquitination activity. Parkin is activated via phosphorylation of Ser-65 in its Ubl domain by PTEN-induced putative kinase 1 (PINK1) and a ubiquitin molecule phosphorylated at a position equivalent to Ser-65 in parkin. Here we have examined the underlying molecular mechanism of phosphorylation of parkin's Ubl domain carrying ARJP-associated substitutions and how altered phosphorylation modulates parkin activation and ubiquitination. We found that three substitutions in the Ubl domain (G12R, R33Q, and R42P) significantly decrease PINK1's ability to phosphorylate the Ubl domain. We noted that two basic loss-of-function substitutions (R33Q and R42P) are close to acidic patches in the proposed PINK1–parkin interface, indicating that ionic interactions at this site may be important for efficient parkin phosphorylation. Increased auto-ubiquitination with unique ubiquitin chain patterns was observed for two other Ubl domain substitutions (G12R and T55I), suggesting that these substitutions, along with phosphorylation, increase parkin degradation. Moreover, Ubl domain phosphorylation decreased its affinity for the potential effector protein ataxin-3, which edits ubiquitin chain building by parkin. Overall, our work provides a framework for the mechanisms of parkin's loss-of-function, indicating an interplay between ARJP-associated substitutions and phosphorylation of its Ubl domain.

Highlights

  • Autosomal recessive juvenile Parkinsonism (ARJP) is an inherited neurodegenerative disease in which 50% of affected individuals harbor mutations in the gene encoding the E3 ligase parkin

  • Parkin is activated via phosphorylation of Ser-65 in its Ubl domain by PTEN-induced putative kinase 1 (PINK1) and a ubiquitin molecule phosphorylated at a position equivalent to Ser-65 in parkin

  • 20 ARJP missense substitutions have been identified in the parkin Ubl domain that contribute to early-onset forms of Parkinson’s disease (PD)

Read more

Summary

Results

The Ubl domain in parkin adopts a classical ␤-grasp fold comprising four ␤-strands, a longer ␣-helix that runs across one side of the ␤-sheet and a shorter ␣-helix that precedes Ser-65, the site of PINK1 phosphorylation (Fig. 1). 20 ARJP missense substitutions have been identified in the parkin Ubl domain that contribute to early-onset forms of Parkinson’s disease (PD). Most of these substitutions are distributed uniformly throughout the Ubl domain structure (Fig. 1). To assess how these mutations alter the overall function of Ser-65-phosphorylated parkin, a subset of substitutions in the Ubl domain, including G12R (UblG12R), P37L (UblP37L), R42P (UblR42P), R33Q (UblR33Q), and T55I (UblT55I), was examined for efficiency of phosphorylation by PINK1, effects on protein stability, alterations in ubiquitination activity, and interaction strength with a proposed partner protein, ataxin-3

ARJP mutants lead to altered phosphorylation efficiencies
Alterations in ubiquitination by a phosphorylated Ubl domain
Effect of phosphorylation
Discussion
Protein constructs and purification
Phosphorylation of parkin and Ubl domain
Unfolding experiments
Yobs ϭ
Parkin ubiquitination assays
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call